Post-earnings recap
Reported
Tue, Nov 4, 2025
EPS actual
$0.16
EPS est.
$0.18
EPS surprise
-12.57%
1-day move
-4.14%
Corcept Therapeutics reported a lower-than-expected EPS for Q3-2025, leading to a 4.14% decline in stock price. The lack of revenue data and guidance contributed to investor uncertainty. Management's cautious tone suggests they are navigating challenges without immediate solutions.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.16 | N/A | -12.57% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed caution regarding the current market environment. They highlighted the importance of maintaining a long-term perspective.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategies despite current performance.
There were no specific updates on product pipelines or market conditions.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—